Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
Status:
Suspended
Trial end date:
2021-10-22
Target enrollment:
Participant gender:
Summary
This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion
in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU
containing chemotherapy combinations.The study will enroll mCRC patients with prior
progression on standard multi-agent combination chemotherapy and progression on regorafenib
monotherapy.